A Postmarketing Surveillance (PMS) Study to Evaluate the Extent to Which Patient Compliance is Influenced by Use of a Variable Titration Regimen at the Start of Treatment of Relapsing Multiple Sclerosis (MS) With Interferon Beta 1a (Rebif®)
Clinical trial NCT01142492 · COMPLETED
Trial details
- NCT number
- NCT01142492
- Sponsor
- Merck KGaA, Darmstadt, Germany
- Status
- COMPLETED
- Study type
- OBSERVATIONAL
- Start date
- 2005-01-01
- Primary completion
- 2008-07-01
- Enrollment
- 403
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.